Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Comparing the effect of two different duration of same drug albendazole in patients with Neurocysticercosis less than or equal to 5 lesions on CT head at the end of 6 months.
The trial will be comparing the effectiveness of short and long duration of albendazole ie 7 and 28 days therapy in patients with parenchymal neurocysticercosis in terms of complete resolution or calcification of cyst on CT head at the end of 6 months after starting albendazole
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Group A | Active Comparator | 7 days of albendazole 15 mg/kg/day |
|
| Group B | Active Comparator | 28 days of albendazole 15 mg/kg/day |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| 7 days of albendazole 15 mg/kg/day | Drug | group A will receive 7 days of oral albendazole 15 mg/kg/day |
|
| Measure | Description | Time Frame |
|---|---|---|
| Number of cyst resolved/ calcified completely after therapy. Resolution or calcification of cyst assessed on CT head at the end of 6 months after starting albendazole | A randomized open labeled control clinical trial to compare the radiological outcome of 7 days versus 28 days albendazole therapy along with steroid in patients with parenchymal neurocysticercosis with lesion load < 5 | 1 year |
| Measure | Description | Time Frame |
|---|---|---|
| Frequency of seizure occurrence | A randomized open labeled control clinical trial to compare the radiological outcome of 7 days versus 28 days albendazole therapy along with steroid in patients with parenchymal neurocysticercosis with lesion load < 5 | 1 year |
| Frequency of occurrence of other symptoms attributable to Neurocysticercosis |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Sheffali Gulati, MD | All India Institute of Medical Sciences | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| sheffali Gulati | New Delhi | National Capital Territory of Delhi | 110029 | India |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| 28 days of albendazole 15 mg/kg/day | Drug | group B will receive 28 days of oral albendazole 15 mg/kg/day |
|
|
A randomized open labeled control clinical trial to compare the radiological outcome of 7 days versus 28 days albendazole therapy along with steroid in patients with parenchymal neurocysticercosis with lesion load < 5 |
| 1 year |
| Frequency of occurrence of side effects of albendazole | A randomized open labeled control clinical trial to compare the radiological outcome of 7 days versus 28 days albendazole therapy along with steroid in patients with parenchymal neurocysticercosis with lesion load < 5 | 1 year |
| ID | Term |
|---|---|
| D020019 | Neurocysticercosis |
| ID | Term |
|---|---|
| D020809 | Central Nervous System Helminthiasis |
| D020807 | Central Nervous System Parasitic Infections |
| D002494 | Central Nervous System Infections |
| D007239 | Infections |
| D010272 | Parasitic Diseases |
| D003551 | Cysticercosis |
| D013622 | Taeniasis |
| D002590 | Cestode Infections |
| D006373 | Helminthiasis |
| D002493 | Central Nervous System Diseases |
| D009422 | Nervous System Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D015766 | Albendazole |
| ID | Term |
|---|---|
| D002219 | Carbamates |
| D000144 | Acids, Acyclic |
| D002264 | Carboxylic Acids |
| D009930 | Organic Chemicals |
| D001562 | Benzimidazoles |
| D006574 | Heterocyclic Compounds, 2-Ring |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
| D006571 | Heterocyclic Compounds |
Not provided
Not provided